Does the media refer more to TNGX or BBIO?

In the previous week, Tango Therapeutics had 11 more articles in the media than BridgeBio Pharma. MarketBeat recorded 17 mentions for Tango Therapeutics and 6 mentions for BridgeBio Pharma. Tango Therapeutics' average media sentiment score of 0.68 beat BridgeBio Pharma's score of 0.29 indicating that Tango Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tango Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive BridgeBio Pharma 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to TNGX or ASND?

In the previous week, Tango Therapeutics had 8 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 17 mentions for Tango Therapeutics and 9 mentions for Ascendis Pharma A/S. Ascendis Pharma A/S's average media sentiment score of 1.04 beat Tango Therapeutics' score of 0.68 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tango Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Ascendis Pharma A/S 3 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, EXEL or TNGX?

Exelixis has higher revenue and earnings than Tango Therapeutics. Tango Therapeutics is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Exelixis $2.32B 5.78 $782.57M $3.18 17.01 Tango Therapeutics $62.38M 64.55 -$101.59M -$0.85 N/A

Does the media prefer EXEL or TNGX?

In the previous week, Tango Therapeutics had 1 more articles in the media than Exelixis. MarketBeat recorded 17 mentions for Tango Therapeutics and 16 mentions for Exelixis. Exelixis' average media sentiment score of 1.18 beat Tango Therapeutics' score of 0.68 indicating that Exelixis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exelixis 11 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tango Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor TNGX or BMRN?

In the previous week, BioMarin Pharmaceutical had 17 more articles in the media than Tango Therapeutics. MarketBeat recorded 34 mentions for BioMarin Pharmaceutical and 17 mentions for Tango Therapeutics. BioMarin Pharmaceutical's average media sentiment score of 0.73 beat Tango Therapeutics' score of 0.68 indicating that BioMarin Pharmaceutical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tango Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive BioMarin Pharmaceutical 13 Very Positive mention(s) 5 Positive mention(s) 9 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ARWR or TNGX?

In the previous week, Tango Therapeutics had 2 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 17 mentions for Tango Therapeutics and 15 mentions for Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals' average media sentiment score of 0.90 beat Tango Therapeutics' score of 0.68 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arrowhead Pharmaceuticals 10 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tango Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Tango Therapeutics (TNGX) Competitors

$23.88 +0.37 (+1.57%)

As of 08/21/2026 04:00 PM Eastern

Compare

TNGX vs. BBIO, ASND, EXEL, BMRN, and ARWR

Should you buy Tango Therapeutics stock or one of its competitors? Tango Therapeutics's main competitors and comparable companies include BridgeBio Pharma (BBIO), Ascendis Pharma A/S (ASND), Exelixis (EXEL), BioMarin Pharmaceutical (BMRN), and Arrowhead Pharmaceuticals (ARWR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Tango Therapeutics compare to BridgeBio Pharma?

Tango Therapeutics (NASDAQ:TNGX) and BridgeBio Pharma (NASDAQ:BBIO) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation, earnings and media sentiment.

In the previous week, Tango Therapeutics had 11 more articles in the media than BridgeBio Pharma. MarketBeat recorded 17 mentions for Tango Therapeutics and 6 mentions for BridgeBio Pharma. Tango Therapeutics' average media sentiment score of 0.68 beat BridgeBio Pharma's score of 0.29 indicating that Tango Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tango Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
BridgeBio Pharma	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Tango Therapeutics has a beta of 1.16, meaning that its share price is 16% more volatile than the broader market. Comparatively, BridgeBio Pharma has a beta of 0.96, meaning that its share price is 4% less volatile than the broader market.

Tango Therapeutics has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -97.03%. BridgeBio Pharma's return on equity of 0.00% beat Tango Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tango Therapeutics	N/A	-25.75%	-23.36%
BridgeBio Pharma	-97.03%	N/A	-61.19%

Tango Therapeutics presently has a consensus price target of $43.46, suggesting a potential upside of 82.00%. BridgeBio Pharma has a consensus price target of $100.79, suggesting a potential upside of 23.67%. Given Tango Therapeutics' higher probable upside, equities research analysts clearly believe Tango Therapeutics is more favorable than BridgeBio Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83

Tango Therapeutics has higher earnings, but lower revenue than BridgeBio Pharma. Tango Therapeutics is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tango Therapeutics	$62.38M	64.55	-$101.59M	-$0.85	N/A
BridgeBio Pharma	$502.08M	31.73	-$724.93M	-$3.57	N/A

79.0% of Tango Therapeutics shares are held by institutional investors. Comparatively, 99.9% of BridgeBio Pharma shares are held by institutional investors. 6.5% of Tango Therapeutics shares are held by company insiders. Comparatively, 14.2% of BridgeBio Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Tango Therapeutics beats BridgeBio Pharma on 9 of the 16 factors compared between the two stocks.

How does Tango Therapeutics compare to Ascendis Pharma A/S?

Tango Therapeutics (NASDAQ:TNGX) and Ascendis Pharma A/S (NASDAQ:ASND) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, risk, valuation, analyst recommendations, profitability, institutional ownership and media sentiment.

Tango Therapeutics has higher earnings, but lower revenue than Ascendis Pharma A/S. Tango Therapeutics is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tango Therapeutics	$62.38M	64.55	-$101.59M	-$0.85	N/A
Ascendis Pharma A/S	$1.05B	15.09	-$258M	$12.89	19.65

Tango Therapeutics has a beta of 1.16, indicating that its stock price is 16% more volatile than the broader market. Comparatively, Ascendis Pharma A/S has a beta of 0.39, indicating that its stock price is 61% less volatile than the broader market.

79.0% of Tango Therapeutics shares are owned by institutional investors. 6.5% of Tango Therapeutics shares are owned by insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Tango Therapeutics presently has a consensus price target of $43.46, indicating a potential upside of 82.00%. Ascendis Pharma A/S has a consensus price target of $300.33, indicating a potential upside of 18.57%. Given Tango Therapeutics' higher probable upside, equities research analysts plainly believe Tango Therapeutics is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	3.05

In the previous week, Tango Therapeutics had 8 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 17 mentions for Tango Therapeutics and 9 mentions for Ascendis Pharma A/S. Ascendis Pharma A/S's average media sentiment score of 1.04 beat Tango Therapeutics' score of 0.68 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tango Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Ascendis Pharma A/S	3 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ascendis Pharma A/S has a net margin of 70.99% compared to Tango Therapeutics' net margin of 0.00%. Ascendis Pharma A/S's return on equity of 32.54% beat Tango Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tango Therapeutics	N/A	-25.75%	-23.36%
Ascendis Pharma A/S	70.99%	32.54%	7.71%

Summary

Ascendis Pharma A/S beats Tango Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Tango Therapeutics compare to Exelixis?

Exelixis (NASDAQ:EXEL) and Tango Therapeutics (NASDAQ:TNGX) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends, valuation and media sentiment.

In the previous week, Tango Therapeutics had 1 more articles in the media than Exelixis. MarketBeat recorded 17 mentions for Tango Therapeutics and 16 mentions for Exelixis. Exelixis' average media sentiment score of 1.18 beat Tango Therapeutics' score of 0.68 indicating that Exelixis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exelixis	11 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tango Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Exelixis has a net margin of 35.33% compared to Tango Therapeutics' net margin of 0.00%. Exelixis' return on equity of 42.17% beat Tango Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exelixis	35.33%	42.17%	31.76%
Tango Therapeutics	N/A	-25.75%	-23.36%

Exelixis has higher revenue and earnings than Tango Therapeutics. Tango Therapeutics is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exelixis	$2.32B	5.78	$782.57M	$3.18	17.01
Tango Therapeutics	$62.38M	64.55	-$101.59M	-$0.85	N/A

Exelixis has a beta of 0.44, suggesting that its stock price is 56% less volatile than the broader market. Comparatively, Tango Therapeutics has a beta of 1.16, suggesting that its stock price is 16% more volatile than the broader market.

Exelixis presently has a consensus target price of $50.07, suggesting a potential downside of 7.42%. Tango Therapeutics has a consensus target price of $43.46, suggesting a potential upside of 82.00%. Given Tango Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Tango Therapeutics is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exelixis	2 Sell rating(s)	11 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.30
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75

85.3% of Exelixis shares are owned by institutional investors. Comparatively, 79.0% of Tango Therapeutics shares are owned by institutional investors. 2.6% of Exelixis shares are owned by company insiders. Comparatively, 6.5% of Tango Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Exelixis beats Tango Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Tango Therapeutics compare to BioMarin Pharmaceutical?

Tango Therapeutics (NASDAQ:TNGX) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, media sentiment, institutional ownership, dividends, profitability and earnings.

BioMarin Pharmaceutical has a net margin of 2.14% compared to Tango Therapeutics' net margin of 0.00%. BioMarin Pharmaceutical's return on equity of 5.32% beat Tango Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tango Therapeutics	N/A	-25.75%	-23.36%
BioMarin Pharmaceutical	2.14%	5.32%	3.69%

Tango Therapeutics presently has a consensus price target of $43.46, suggesting a potential upside of 82.00%. BioMarin Pharmaceutical has a consensus price target of $88.83, suggesting a potential upside of 33.17%. Given Tango Therapeutics' higher probable upside, research analysts clearly believe Tango Therapeutics is more favorable than BioMarin Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75
BioMarin Pharmaceutical	1 Sell rating(s)	6 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	2.75

BioMarin Pharmaceutical has higher revenue and earnings than Tango Therapeutics. Tango Therapeutics is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tango Therapeutics	$62.38M	64.55	-$101.59M	-$0.85	N/A
BioMarin Pharmaceutical	$3.22B	4.01	$348.90M	$0.37	180.27

79.0% of Tango Therapeutics shares are owned by institutional investors. Comparatively, 98.7% of BioMarin Pharmaceutical shares are owned by institutional investors. 6.5% of Tango Therapeutics shares are owned by company insiders. Comparatively, 0.7% of BioMarin Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Tango Therapeutics has a beta of 1.16, suggesting that its stock price is 16% more volatile than the broader market. Comparatively, BioMarin Pharmaceutical has a beta of 0.24, suggesting that its stock price is 76% less volatile than the broader market.

In the previous week, BioMarin Pharmaceutical had 17 more articles in the media than Tango Therapeutics. MarketBeat recorded 34 mentions for BioMarin Pharmaceutical and 17 mentions for Tango Therapeutics. BioMarin Pharmaceutical's average media sentiment score of 0.73 beat Tango Therapeutics' score of 0.68 indicating that BioMarin Pharmaceutical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tango Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
BioMarin Pharmaceutical	13 Very Positive mention(s)	5 Positive mention(s)	9 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

BioMarin Pharmaceutical beats Tango Therapeutics on 12 of the 16 factors compared between the two stocks.

How does Tango Therapeutics compare to Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Tango Therapeutics (NASDAQ:TNGX) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, analyst recommendations, institutional ownership, risk, earnings, valuation and dividends.

In the previous week, Tango Therapeutics had 2 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 17 mentions for Tango Therapeutics and 15 mentions for Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals' average media sentiment score of 0.90 beat Tango Therapeutics' score of 0.68 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arrowhead Pharmaceuticals	10 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tango Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Arrowhead Pharmaceuticals has higher revenue and earnings than Tango Therapeutics. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Tango Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arrowhead Pharmaceuticals	$829.45M	14.79	-$1.63M	-$2.25	N/A
Tango Therapeutics	$62.38M	64.55	-$101.59M	-$0.85	N/A

Tango Therapeutics has a net margin of 0.00% compared to Arrowhead Pharmaceuticals' net margin of -47.79%. Tango Therapeutics' return on equity of -25.75% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arrowhead Pharmaceuticals	-47.79%	-60.06%	-17.37%
Tango Therapeutics	N/A	-25.75%	-23.36%

62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. Comparatively, 79.0% of Tango Therapeutics shares are held by institutional investors. 3.6% of Arrowhead Pharmaceuticals shares are held by insiders. Comparatively, 6.5% of Tango Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Arrowhead Pharmaceuticals has a beta of 1.27, indicating that its stock price is 27% more volatile than the broader market. Comparatively, Tango Therapeutics has a beta of 1.16, indicating that its stock price is 16% more volatile than the broader market.

Arrowhead Pharmaceuticals currently has a consensus target price of $97.33, suggesting a potential upside of 11.74%. Tango Therapeutics has a consensus target price of $43.46, suggesting a potential upside of 82.00%. Given Tango Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Tango Therapeutics is more favorable than Arrowhead Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

Tango Therapeutics beats Arrowhead Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

Get Tango Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TNGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TNGX vs. The Competition

Export

Metric	Tango Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$4.03B	$4.01B	$7.37B	$12.85B
Dividend Yield	N/A	3.64%	2.53%	11.08%
P/E Ratio	-28.09	11.62	272.60	24.24
Price / Sales	64.55	1,338.17	618.96	99.81
Price / Cash	N/A	105.14	78.62	53.99
Price / Book	3.93	16.80	13.05	6.20
Net Income	-$101.59M	-$12.50M	$3.47B	$348.59M
7 Day Performance	-6.72%	3.29%	2.09%	0.08%
1 Month Performance	-13.01%	8.23%	6.64%	3.88%
1 Year Performance	246.09%	55.05%	25.02%	16.98%

Tango Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TNGX Tango Therapeutics	2.481 of 5 stars	$23.88 +1.6%	$43.46 +82.0%	+246.1%	$4.03B	$62.38M	N/A	90	Analyst Forecast Analyst Revision
BBIO BridgeBio Pharma	3.2352 of 5 stars	$82.27 +3.0%	$100.79 +22.5%	+66.1%	$16.06B	$713.07M	N/A	400	Insider Trade
ASND Ascendis Pharma A/S	4.6059 of 5 stars	$250.38 +1.2%	$299.24 +19.5%	+30.4%	$15.60B	$814.57M	19.40	1,189	Positive News Earnings Report Analyst Forecast Insider Trade
EXEL Exelixis	3.3988 of 5 stars	$52.98 +1.3%	$49.79 -6.0%	+40.0%	$13.11B	$2.44B	16.63	1,077	News Coverage Positive News Analyst Forecast
BMRN BioMarin Pharmaceutical	4.7599 of 5 stars	$67.12 +0.7%	$88.41 +31.7%	+13.9%	$12.98B	$3.41B	181.25	3,221	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TNGX) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tango Therapeutics (TNGX) Competitors

TNGX vs. BBIO, ASND, EXEL, BMRN, and ARWR

How does Tango Therapeutics compare to BridgeBio Pharma?

Summary

How does Tango Therapeutics compare to Ascendis Pharma A/S?

Summary

How does Tango Therapeutics compare to Exelixis?

Summary

How does Tango Therapeutics compare to BioMarin Pharmaceutical?

Summary

How does Tango Therapeutics compare to Arrowhead Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNGX vs. The Competition

Tango Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tango Therapeutics (TNGX) Competitors

TNGX vs. BBIO, ASND, EXEL, BMRN, and ARWR

How does Tango Therapeutics compare to BridgeBio Pharma?

Does the media refer more to TNGX or BBIO?

Which has more volatility and risk, TNGX or BBIO?

Is TNGX or BBIO more profitable?

Do analysts recommend TNGX or BBIO?

Which has stronger earnings and valuation, TNGX or BBIO?

Do insiders & institutionals have more ownership in TNGX or BBIO?

Summary

How does Tango Therapeutics compare to Ascendis Pharma A/S?

Which has better valuation and earnings, TNGX or ASND?

Which has more volatility and risk, TNGX or ASND?

Do insiders and institutionals hold more shares of TNGX or ASND?

Do analysts rate TNGX or ASND?

Does the media refer more to TNGX or ASND?

Is TNGX or ASND more profitable?

Summary

How does Tango Therapeutics compare to Exelixis?

Does the media prefer EXEL or TNGX?

Is EXEL or TNGX more profitable?

Which has stronger earnings & valuation, EXEL or TNGX?

Which has more volatility & risk, EXEL or TNGX?

Do analysts rate EXEL or TNGX?

Do insiders & institutionals hold more shares of EXEL or TNGX?

Summary

How does Tango Therapeutics compare to BioMarin Pharmaceutical?

Is TNGX or BMRN more profitable?

Do analysts prefer TNGX or BMRN?

Which has preferable earnings and valuation, TNGX or BMRN?

Do insiders and institutionals have more ownership in TNGX or BMRN?

Which has more volatility & risk, TNGX or BMRN?

Does the media favor TNGX or BMRN?

Summary

How does Tango Therapeutics compare to Arrowhead Pharmaceuticals?

Does the media refer more to ARWR or TNGX?

Which has better valuation & earnings, ARWR or TNGX?

Is ARWR or TNGX more profitable?

Do insiders & institutionals have more ownership in ARWR or TNGX?

Which has more risk & volatility, ARWR or TNGX?

Do analysts recommend ARWR or TNGX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNGX vs. The Competition

Tango Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools